News

Mor Research Applications

Met Mor’s team at HLTH Europe 2024, June 17-20, Amsterdam

Companies and investors interested in meeting please contact: sari@mor-research.com

Can-Fite

FDA grants IND clearance

For NAMODENOSON to treat MASH patients in phase IIb study

Mor Research Applications

Met Mor’s team at BIOMED 2024, May 21-23, Tel Aviv

Companies, entrepreneurs and investors please contact: sari@mor-research.com

EyeYon Medical

Early Outcomes of study with synthetic endothelial replacement membrane

The implant improves central corneal transparency and visual acuity in patients with failed EK

Can-Fite

CAN-FITE submits IND application to FDA

to conduct phase IIb trial of Namodenoson in MASH patients

Mediwound

NexoBrid BLA to Include Pediatric Patients

FDA has Accepted for Review the Supplement to NexoBrid for Pediatric Patients with Severe Thermal Burns

Mor Research Applications

Met Mor’s team at Mixiii 2024, March 5-6, Jerusalem

Companies, entrepreneurs and investors please contact: sari@mor-research.com

NGS Solutions

NGS’ Healthy Heights Available at Walmart

Walmart now stocking Healthy Heights with significant opportunities for expansion

Mor Research Applications

IIA invests 25M NIS in innovation center in Be’er Sheva

Synergy 7 jointly owned by Mor, Ben Gurion U, B.G. Negev, Soroka , Elbit , Incubit Technological Entrepreneurship and Merage

Exero Medical

Exero’s Pivotal Clinical Study Approved by WCG

Exero’s multi-center study expected to commence during Q1 2024.

12